Cabaletta Bio expects to complete $35M stock and warrant sale this week to advance cell therapy candidate

The company's lead cell therapy candidate is being developed to treat multiple autoimmune diseases.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 12, 2022 Category: Pharmaceuticals Authors: John George Source Type: news